Diabetic Cardiomyopathies
"Diabetic Cardiomyopathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Descriptor ID |
D058065
|
| MeSH Number(s) |
C14.280.238.235 C19.246.099.625
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diabetic Cardiomyopathies".
Below are MeSH descriptors whose meaning is more specific than "Diabetic Cardiomyopathies".
This graph shows the total number of publications written about "Diabetic Cardiomyopathies" by people in this website by year, and whether "Diabetic Cardiomyopathies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diabetic Cardiomyopathies" by people in Profiles.
-
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. Adv Drug Deliv Rev. 2021 09; 176:113904.
-
Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy. Cardiovasc Drugs Ther. 2020 12; 34(6):835-848.
-
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. Cardiovasc Drugs Ther. 2020 08; 34(4):443-461.
-
Examining the Relationship and Prognostic Implication of Diabetic Status and Extracellular Matrix Expansion by Cardiac Magnetic Resonance. Circ Cardiovasc Imaging. 2020 07; 13(7):e011000.
-
Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart. Basic Res Cardiol. 2020 01 07; 115(2):10.
-
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res Cardiol. 2019 08 06; 114(5):35.
-
Left atrial remodeling, hypertrophy, and fibrosis in mouse models of heart failure. Cardiovasc Pathol. 2017 Sep - Oct; 30:27-37.
-
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
-
Dysregulation of RBFOX2 Is an Early Event in Cardiac Pathogenesis of Diabetes. Cell Rep. 2016 06 07; 15(10):2200-2213.
-
Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway. Cardiovasc Diabetol. 2016 May 06; 15:75.